We conclude that monthly and 3-month sustained release (depot) formulations of leuprolide acetate provide consistent, uniform suppression of serum testosterone throughout the respective dosing intervals, and that the initial depot injection of each formulation provides sufficient pituitary desensitization to prevent agnostic stimulation of serum testosterone during chronic treatment.